In this week’s OIS Podcast, Dr. Ehsan Sadri speaks with Bob Dempsey who just assumed the CEO role for TearClear. Let’s hear how Bob’s experience taking Xiidra to market for Shire led him to the driver’s seat for one of the most promising new drug-delivery companies.
TearClear Completes Initial Close of $25MM Series B Financing led by Visionary Ventures, Bluestem Capital, and Flying L. Additionally, TearClear has appointed Robert Dempsey to the CEO role. Robert Dempsey and Bill Link were interviewed by Eyewire news about the latest financing and CEO appointment.
TearClear aims to be the premier specialty pharmaceutical company assuring reliable delivery of preservative-free ophthalmic drugs from preserved multi-dose solutions.
TearClear closes series A financing and introduces leadership team of accomplished ophthalmology veterans with the proceeds going to advance the development of the Company’s delivery system for preservative-free ophthalmic drugs.